Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Lupus

Therapeutic area intelligence for Lupus with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 2

Companies

AstraZeneca →

Assets

litifilimab (BIIB059) →

Recent signals(2)

RegulatoryJuly 29, 2026

FDA Accepts Application for SAPHNELO (Anifrolimab-FNIA) by AstraZeneca

The FDA has accepted the Biologics License Application for SAPHNELO (anifrolimab-FNIA) submitted by AstraZeneca.

ClinicalJuly 15, 2026

Biogen's Litifilimab (BIIB059) Study Targets Active Cutaneous Lupus Erythematosus

Biogen is conducting a 2-part clinical trial to evaluate the efficacy and safety of litifilimab in patients with active cutaneous lupus erythematosus.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.